Nealon Communicators’ Lectures Honor Late NCI Employee

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 2
Volume 9
Issue 2

BETHESDA, Md-The National Cancer Institute has named a new lecture series for Eleanor Nealon, a long-time employee who died of recurrent breast cancer on Oct. 22.

BETHESDA, Md—The National Cancer Institute has named a new lecture series for Eleanor Nealon, a long-time employee who died of recurrent breast cancer on Oct. 22.

The Eleanor Nealon Extraordinary Communicators’ Lecture Series will focus on the communication of science to the public and will feature “outstanding communicators who have advanced an understanding of science through their skill in communications.” Three speakers will be selected each year, drawn from the areas of technology, business, academia, the media, and the advocacy community. Ms. Nealon was an 18-year employee of the Institute. Prior to her death, she served as director of the NCI Office of Liaison

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content